What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer: A Case-based Session for Urologists, Advanced Practice Providers and Teams Webcast (2021)

This course will include case-based presentations and ARS in three distinct diseases groups: hormone-sensitive metastatic prostate cancer (HSMPC); non-metastatic castrate resistant prostate cancer (M0CRPC) and metastatic CRPC (MCRPC) to educate urologists, APP's and their teams to identify and understand  the many new FDA-approved agents, as well as existing standard therapies. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.  We aim to allow urologists and their practice teams to be comfortable prescribing the following agents: abiraterone, enzalutamide, apalutamide, daralutamide, radium-223, denosumab, Sipuleucel-T and understand systemic chemotherapy, PARP inhibitors and emerging immunotherapy.

ACKNOWLEDGEMENTS

Independent educational grant support provided by: 

  • Amgen
  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Exact Sciences Corporation
  • Janssen Biotech, Inc. Administered by Janssen Scientific Affairs, LLC
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme   

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. List the three main advanced prostate cancer disease states (HSMPC); M0 CRPC and M1 CRPC) and be able to identify these patients in urologic practice.
  2. Identify FDA-hormonal and non-hormonal therapies for use in each of these three disease states: HSMPC, M0 CRPC, M1 CRPC.
  3. Demonstrate the safe use and unique mechanism of action and side effects of new and existing agents.
  4. Explain the sequencing of novel therapies and be able to identify patient progression of disease by PSA, imaging and signs and symptoms.
  5. Work in team care including urologists, advanced practice providers, oncology nursing, oncology pharmacy, medical oncology and radiation oncology and their support staffs.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
09/15/2021
Course expires: 
09/15/2022
Rating: 
0

Education Council Disclosures

 Education Council Disclosures 2021

COI Review Work Group Disclosures

 COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Judd Moul, MD, FACS

has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Genomic Health;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Astellas;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Janssen- J and J;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Sanofi-Aventis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tolmar;.
has a financial relationship (Health Publishing (Oncology)) with Up to Date;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Blue Earth Diagnostics;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Exosome Dx ;.
has a financial relationship (Other (Oncology)) with Best Doctors;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Ferring;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Theralogix;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Dendreon;.
Faculty(s)

Lawrence Karsh, MD

has a financial relationship (Scientific Study or Trial (Oncology)) with Vaxiion;.
has a financial relationship (Consultant or Advisor (Oncology)) with OPKO;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tolmar;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with ABBVIE;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Veru Pharmaceuticals;.
has a financial relationship (Consultant or Advisor (Oncology)) with GenomeDx BIosciences ;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Nucleix ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with UROGPO;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (General Urology)) with Swan Valley Medical;.
has a financial relationship (Consultant or Advisor (Oncology)) with Precision Biopsy ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myriad Genetics;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Exact Sciences;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sesen;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Genomic Health;.
has a financial relationship (Consultant or Advisor (Oncology)) with Boston Scientific;.
has a financial relationship (Consultant or Advisor (Oncology)) with Medivation;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Minomic ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with CUSP;.
has a financial relationship (Consultant or Advisor (Oncology)) with Arivan Research;.
has a financial relationship (Scientific Study or Trial (Oncology)) with FKD;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Nymox ;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Augmenix ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clovis;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Bristol Myers Squibb;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Epizyme;.
has a financial relationship (Scientific Study or Trial (Oncology)) with QED;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Tavanta;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Genetech/Hoffman;.
has a financial relationship (Consultant or Advisor (Oncology)) with EMD Serono;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Hinova;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Cepheid ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Arivan Research;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant ;.
has a financial relationship (Investment Interest (Oncology)) with 3D Biopsy ;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Precision Med;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Bayer;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Exelexis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astra-Zeneca;.
has a financial relationship (Consultant or Advisor (Oncology)) with Kiadis;.
has a financial relationship (Consultant or Advisor (Oncology)) with UroGPO;.
has a financial relationship (Scientific Study or Trial (Oncology)) with NeoGenomic Laboratories;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with BioXcel;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Siemans;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Urogen;.

Evan Yu, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Oncology)) with Exelixis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: September, 2021
Expiration Date: September, 2022

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.